本帖最后由 老马 于 2012-1-13 21:20 编辑
2 `" k. D/ H. j( r! P0 R4 ]$ B, r: |* l) {" O6 [5 b0 a
爱必妥和阿瓦斯丁的比较
9 k. c$ J0 G4 X8 `8 Q
5 i7 C- ^. t9 a# m; c
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 Q* k6 ]0 f& g0 d' w5 ?5 {+ v
! w1 p( T' b- B$ m5 \7 x
# F& s) L7 T) N
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/1 _- P/ Y. n7 {- B; I$ ]
==================================================1 q: P8 C" v) H$ y( x2 I6 G) Y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)& O1 l" s& w+ h3 E0 L
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. S3 f; Z/ y1 T u7 C+ }
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 l2 h/ s9 y4 @
|
显身卡
2 H3 z! n$ i: I
